Phase 2 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 21 and 65 years old, of any sex, race, or ethnicity
- You have had a stroke (either a blockage or bleeding in the brain) that was confirmed by a CT or MRI scan within the past year
- You have been experiencing depression since your stroke, with symptoms lasting at least 2 weeks and scoring 17 or higher on a standard depression rating scale called the HAM-D
Who may not be able to join:
- You have a history of misusing or being dependent on drugs, recreational substances, or alcohol
- You have serious liver or kidney problems
- You are currently pregnant or planning to become pregnant
- You have recently given birth or are currently breastfeeding
- You have a history of attempting suicide
- You are currently experiencing psychosis (losing touch with reality) or thoughts of suicide that require immediate medical attention
- You have started or changed the dose of antidepressant medication within the past 12 weeks before joining the trial
- You were diagnosed with Bipolar disorder, schizophrenia, or depression that did not respond to treatment before your stroke occurred
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nada El Husseini, MD, Duke University
Phone: 919-684-1992
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with treatment emergent adverse events (TEAEs) after starting zuranolone; Severity of suicidal ideation after starting zuranolone as measured by the Columbia Suicide Severity Rating Scale (C-SSRS); Severity of somnolence after starting zuranolone as measured by the Epworth Sleepiness Scale (ESS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.